Kalaris Therapeutics, Inc.
KLRS
$3.41
-$0.06-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 45.79% | 41.94% | 37.20% | -9.59% | -- |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -100.00% | -100.00% | -99.51% | 1,585.51% | -- |
| Total Other Non-Cash Items | -87.44% | -87.22% | -88.58% | -157.72% | -- |
| Change in Net Operating Assets | 134.11% | -102.31% | 261.41% | 72.91% | -- |
| Cash from Operations | -27.55% | -80.20% | -85.63% | -130.99% | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | -100.00% | -62.44% | 74.85% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,402,700.00% | 1,402,366.67% | 1,399,900.00% | 100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -96.32% | -95.92% | 4,459.79% | 102,393.68% | -- |
| Cash from Financing | -60.24% | -61.57% | 709.86% | 523.41% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -154.73% | -169.14% | 6,434.25% | 2,693.05% | -- |